Lehagen, a technology distribution company with strong global partners, has signed a deal worth of 3 million USD with multiple partners across India. With Lehagen and Cascade sign a contract to bring BioPurifiers and BioSense technologies to India
Cascade Air Technologies Incorporated. Cascade Air Technologies Inc is a bio-purification and air quality sensing company based in the USA. Cascade manufacture hyper-local BioPurification and BioSense products to kill viruses, bacteria, and other microorganisms and it reduces particulate matter, volatile chemical compounds, and other harmful pollutants.
This alliance aims to provide safety in public spaces like malls, commercial office spaces, schools, colleges, shops, supermarkets, banks, and ATMs, where more people gather. Cascade Air Technologies endeavour to create both indoor residences and community indoor spaces a much more hygienic and healthy lifestyle by concentrating on air purification and bio purifications by eliminating the microorganisms.
“Every human being deserves to live in a clean, green, and BioPurified environment. Lehagen aims to provide a clean environment across Asia.”
– Prasanna, Commercial Director, Lehagen Private Limited
“Lehagen with a strong network dealers & distributors trained 1200+ system integrators across India, Middle East, Africa, Europe & ASEAN countries, we built relationships and support entrepreneurs in taking quality products, we look forward to using this our network to provide bio purified air to people.”
– Mohammed Ajhas, Sales Director, Lehagen Private Limited
Takeda and Frazier Healthcare Partners Announce Collaboration to Launch HilleVax, Inc. to Develop Clinical Stage Norovirus Vaccine Candidate
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (Takeda) and Frazier Healthcare Partners (Frazier) today announced a collaboration to launch HilleVax, Inc. (HilleVax), a biopharmaceutical company to develop and commercialize Takeda’s norovirus vaccine candidate. Takeda has granted a license to HilleVax for the exclusive development and commercialization rights to its norovirus vaccine candidate, […]
